Information de reference pour ce titreAccession Number: | 01445386-200804010-00019.
|
Author: | Ruano, Yolanda BcSc 1; Mollejo, Manuela PhD, MD 2; Camacho, Francisca I. PhD, MD 3; de Lope, Angel Rodriguez PhD, MD 4; Fiano, Concepcion MD 5; Ribalta, Teresa PhD, MD 6; Martinez, Pedro BcSc 1; Hernandez-Moneo, Jose-Luis MD 4; Melendez, Barbara PhD 1,*,+
|
Institution: | (1)Genetics Department, Virgen de la Salud Hospital, Toledo, Spain (2)Department of Pathology, Virgen de la Salud Hospital, Toledo, Spain (3)Department of Pathology, Getafe University Hospital, Madrid, Spain (4)Neurosurgery, Virgen de la Salud Hospital, Toledo, Spain (5)Department of Pathology, Xeral-Cies Hospital Complex, Vigo, Spain (6)Department of Pathology, Clinic Hospital, Barcelona, Spain (*)Address for reprints: Genetics Department, Hospital Virgen de la Salud, Avenida Barber 30, 45004-Toledo, Spain
|
Title: | |
Source: | Cancer. 112(7):1575-1584, April 1, 2008.
|
Abstract: | BACKGROUND. Knowledge of the molecular mechanisms involved in the biology of glioblastoma multiforme (GBM) is essential for the identification of candidate prognostic markers, new putative therapeutic targets, and early detection strategies predictive of survival.
METHODS. The authors performed expression-profiling analyses in a series of primary GBMs by using complementary DNA microarrays. Validation of putative targets was performed in large series of GBMs by immunohistochemistry on tissue microarrays, real-time quantitative reverse transcription-polymerase chain reaction analysis, and Western blot analysis.
RESULTS. The expression signature consisted of 159 up-regulated genes and 186 down-regulated genes. Most of these genes were involved in cell adhesion, signal transduction, cell cycle, apoptosis, and angiogenesis. Among the genes from the molecular signature, annexin 1 (ANXA1) and ubiquitin-specific protease 7 (USP7) were evaluated in wider series of GBMs. ANXA1 analysis carried out in different types of gliomas revealed exclusive overexpression in astrocytomas. Furthermore, survival analysis by using functional clusters of genes related with cancer and glioma biology revealed 7 genes involved in the PI3K-signaling pathway that presented a significant association with clinical outcome. Among these genes, positive expression of BCL2-associated X protein (BAX) was associated significantly with better survival in a larger series of tumors. In addition, activation of the PI3K/Akt pathway was demonstrated in this set of GBMs.
CONCLUSIONS. The authors concluded that there is a significant role for PI3K pathway survival-related genes in patients with GBM, and putative prognostic markers associated with glioma tumorigenesis were identified. The detailed study of these candidate genes and the molecular pathways regulating PI3K activation reveal that they are promising targets for the clinical management of patients with glioma. Cancer 2008. (C) 2008 American Cancer Society.
: Expression profiling analyses in primary glioblastoma multiforme (GBM) tumors revealed a central role for the phosphatidylinositol 3'-kinase pathway in the pathogenesis and clinical outcome of patients with GBM.
Copyright (C) 2008 John Wiley & Sons, Inc.
|
Author Keywords: | glioblastoma multiforme; expression profiling; phosphatidylinositol 3-kinase pathway; survival-related genes; molecular signature.
|
References: | 1. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999; 91: 1382-1390.
2. DeAngelis L. Primary central nervous system lymphomas. Curr Treat Options Oncol. 2001; 2: 309-318.
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003; 21: 1624-1636.
4. Gudinaviciene I, Pranys D, Juozaityte E. Impact of morphology and biology on the prognosis of patients with gliomas. Medicina (Kaunas). 2004; 40: 112-120.
5. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004; 3: 430-446.
6. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol. 1999; 1: 44-51.
7. Watanabe K, Tachivana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996; 6: 217-223.
8. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta. 2000; 1470: M21-M35.
9. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2: 489-501.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874.
11. Yamanaka R, Arao T, Yajima N, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene. 2006; 25: 5994-6002.
12. Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia. 2005; 7: 7-16.
13. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA. 2005; 102: 5814-5819.
14. Mischel PS, Shai R, Shi T, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003; 22: 2361-2373.
15. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005; 65: 1678-1686.
16. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003; 22: 4918-4923.
17. Kleihues P, Cavnee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer; 2000.
18. Tracey L, Villuendas R, Ortiz P, et al. Identification of genesinvolved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol. 2002; 161: 1825-1837.
19. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res [serial online]. 2002; 30: e15.
20. Qin LX, Kerr KF. Empirical evaluation of data transformations and ranking statistics for microarray analysis. Nucleic Acids Res. 2004; 32: 5471-5479.
21. Vaquerizas JM, Dopazo J, Diaz-Uriarte R. DNMAD: web-based diagnosis and normalization for microarray data. Bioinformatics. 2004; 20: 3656-3658.
22. Herrero J, Diaz-Uriarte R, Dopazo J. Gene expression data preprocessing. Bioinformatics. 2003; 19: 655-656.
23. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003; 9: 3606-3614.
24. Hu N, Qian L, Hu Y, et al. Quantitative real-time RT-PCR validation of differential mRNA expression of SPARC, FADD, Fascin, COL7A1, CK4, TGM3, ECMI, PPL and EVPL in esophageal squamous cell carcinoma. BMC Cancer [serial online]. 2006; 6: 33.
25. Al-Shahrour F, Diaz-Uriarte R, Dopazo J. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics. 2004; 20: 578-580.
26. Rodriguez A, Martinez N, Camacho FI, et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res. 2004; 10: 6796-6806.
27. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005; 106: 1831-1838.
28. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001; 125: 279-284.
29. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesis pathway maps and 3 novel MYC-interacting genes in human gliomas. Cancer Res. 2005; 65: 8679-8689.
30. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006; 9: 287-300.
31. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005; 97: 880-887.
32. Sasaki H, Sato Y, Kondo S, et al. Expression of the periostin mRNA level in neuroblastoma. J Pediatr Surg. 2002; 37: 1293-1297.
33. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004; 5: 329-339.
34. Johnson MD, Kamso-Pratt J, Pepinsky RB, Whetsell WO Jr. Lipocortin-1 immunoreactivity in central and peripheral nervous system glial tumors. Hum Pathol. 1989; 20: 772-776.
35. Pepinsky RB. Phosphorylation of lipocortin-1 by the epidermal growth factor receptor. Methods Enzymol. 1991; 198: 260-272.
36. Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle. 2005; 4: 1166-1170.
37. Sheng Y, Saridakis V, Sarkari F, et al. Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol. 2006; 13: 285-291.
38. Cartron PF, Oliver L, Martin S, et al. The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients. Hum Mol Genet. 2002; 11: 675-687.
39. Khera S, Chang NS. TIAF1 participates in the transforming growth factor beta1-mediated growth regulation. Ann N Y Acad Sci. 2003; 995: 11-21.
40. Schultz L, Khera S, Sleve D, Heath J, Chang NS. TIAF1 and p53 functionally interact in mediating apoptosis and silencing of TIAF1 abolishes nuclear translocation of serine 15-phosphorylated p53. DNA Cell Biol. 2004; 23: 67-74.
41. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. 2006; 66: 5618-5623.
42. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006; 12: 3935-3941.
43. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378: 785-789.
44. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004; 64: 1987-1996.
45. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998; 12: 3499-3511.
|
Language: | English.
|
Document Type: | Original Article: Original Articles; Disease Site; Neuro-Oncology.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0008-543X
|
DOI Number: | https://dx.doi.org/10.1002/cncr....- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|